Graduate Institute of Basic Medical Science, China Medical University, Taichung, Taiwan.
Department of General Surgery, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan.
Mol Neurobiol. 2018 Sep;55(9):7487-7499. doi: 10.1007/s12035-018-0933-z. Epub 2018 Feb 9.
Inhibition of microglial over-activation is an important strategy to counter balance neurodegenerative progression. We previously demonstrated that the adenosine monophosphate-activated protein kinase (AMPK) may be a therapeutic target in mediating anti-neuroinflammatory responses in microglia. Brain-derived neurotrophic factor (BDNF) is one of the major neurotrophic factors produced by astrocytes to maintain the development and survival of neurons in the brain, and have recently been shown to modulate homeostasis of neuroinflammation. Therefore, the present study focused on BDNF-mediated neuroinflammatory responses and may provide an endogenous regulation of neuroinflammation. Among the tested neuroinflammation, epigallocatechin gallate (EGCG) and minocycline exerted BDNF upregulation to inhibit COX-2 and proinflammatory mediator expressions. Furthermore, both EGCG and minocycline upregulated BDNF expression in microglia through AMPK signaling. In addition, minocycline and EGCG also increased expressions of erythropoietin (EPO) and sonic hedgehog (Shh). In the endogenous modulation of neuroinflammation, astrocyte-conditioned medium (AgCM) also decreased the expression of COX-2 and upregulated BDNF expression in microglia. The anti-inflammatory effects of BDNF were mediated through EPO/Shh in microglia. Our results indicated that the BDNF-EPO-Shh novel-signaling pathway underlies the regulation of inflammatory responses and may be regarded as a potential therapeutic target in neurodegenerative diseases. This study also reveals a better understanding of an endogenous crosstalk between astrocytes and microglia to regulate anti-inflammatory actions, which could provide a novel strategy for the treatment of neuroinflammation and neurodegenerative diseases.
抑制小胶质细胞的过度激活是对抗神经退行性进展的重要策略。我们之前的研究表明,腺苷单磷酸激活的蛋白激酶(AMPK)可能是介导小胶质细胞抗炎反应的治疗靶点。脑源性神经营养因子(BDNF)是星形胶质细胞产生的主要神经营养因子之一,用于维持大脑中神经元的发育和存活,最近已被证明可调节神经炎症的稳态。因此,本研究集中于 BDNF 介导的神经炎症反应,可能为神经炎症提供内源性调节。在测试的神经炎症中,表没食子儿茶素没食子酸酯(EGCG)和米诺环素上调 BDNF 以抑制 COX-2 和促炎介质的表达。此外,EGCG 和米诺环素均通过 AMPK 信号转导上调小胶质细胞中的 BDNF 表达。此外,米诺环素和 EGCG 还增加了促红细胞生成素(EPO)和 sonic hedgehog(Shh)的表达。在神经炎症的内源性调节中,星形胶质细胞条件培养基(AgCM)也降低了 COX-2 的表达并上调了小胶质细胞中的 BDNF 表达。BDNF 的抗炎作用是通过 EPO/Shh 在小胶质细胞中介导的。我们的研究结果表明,BDNF-EPO-Shh 新型信号通路是炎症反应调节的基础,可能成为神经退行性疾病的潜在治疗靶点。本研究还揭示了星形胶质细胞和小胶质细胞之间的内源性串扰,以调节抗炎作用,为神经炎症和神经退行性疾病的治疗提供了新的策略。